Priscilla will be presenting in a few hours....I just found this information.
A bit late now to try to join in for this presentation.
See if a replay is available tomorrow....words in the preview, I think are a little different from the past from Priscilla.
The success, or even positive hint from her tonight..... is just massive for this company.
"Shifting clinical paradigms in primary and metastatic brain tumors..." not bad when the KZA drug is 43% of the trial, in 800,000 annual brain mets PA around the world.
_________________________
To join a seminar, please register here.
|
Column 1 |
| 1 |
19 Jan 202112:00PM - 01:00PMPriscilla Brastianos, MD (MGH): Shifting clinical paradigms in primary and metastatic brain tumors using genomics (Physics Seminar)Goitein RoomIn this presentation, I will present our ongoing work on our genomic characterization of primary and metastatic brain tumors. We have identified novel drivers and potentially clinically actionable mutations in meningiomas, craniopharyngiomas and brain metastases. We have translated these findings to clinical trials, including novel national multicenter genomically-driven trials.
Short Bio
Originally from Vancouver, BC, Dr. Priscilla Brastianos completed her medical school and internal medicine residency at Johns Hopkins School of Medicine and fellowship training in hematology/oncology and neuro-oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. She is now director of the Central Nervous System Metastasis Center at Massachusetts General Hospital and leads a multi-R01-funded laboratory. Dr. Brastianos’ research focuses on understanding the genomic mechanisms that drive primary and metastatic brain tumors. She has lead studies which have identified novel therapeutic targets in brain tumors. She has more than 125 scientific publications and has translated her scientific findings to national multicenter trials. She also leads a multidisciplinary central nervous system metastasis clinic at Massachusetts General Hospital/Harvard Medical School. She has received a number of awards for her work including a ‘NextGen Star’ award by the American Association for Cancer Research, a Damon Runyon Clinical Investigator Award, a Breast Cancer Research Foundation Award, a Susan G. Komen Career Catalyst Award, and the American Brain Tumor Association Joel Gingras Award.
|
